Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLUL | P15104 | 1/20 | 0.48 |
| ▸ | GRM8 | O00222 | 2/20 | 0.47 |
| ▸ | GRM6 | O15303 | 2/20 | 0.47 |
| ▸ | GRM7 | Q14831 | 2/20 | 0.47 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.47 |
| ▸ | PGK1 | P00558 | 1/20 | 0.45 |
| ▸ | PGK2 | P07205 | 1/20 | 0.45 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.45 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.45 |
| ▸ | GSR | P00390 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 1/20 | 0.45 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.45 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.45 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.45 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.45 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.45 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.45 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1332612 | 1.00 | GLUL (0.48) | GLULGRM8GRM6GRM7GRM4 | |
| Threonine SCHEMBL6937630 | 0.87 | LAP3 (0.40) | GLULGRM8GRM6GRM7GRM4 | |
| SCHEMBL8420222 | 0.84 | GLUL (0.46) | GLULGRM8GRM6GRM7GRM4 | |
| SCHEMBL30690147 | 0.84 | GLUL (0.46) | GLULGRM8GRM6GRM7GRM4 | |
| SCHEMBL9711127 | 0.84 | GLUL (0.46) | GLULGRM8GRM6GRM7GRM4 | |
| Dexfosfoserine SCHEMBL27915644 | 0.81 | PGK1 (0.57) | PGK1PGK2 | |
| Lysine SCHEMBL25386576 | 0.81 | GSR (0.65) | GLULGSR | |
| Tyrosine SCHEMBL9732469 | 0.81 | SLC7A5 (0.65) | GRM8GRM4 | |
| Threonine SCHEMBL382180 | 0.81 | PGD (0.36) | GLULPGK1PGK2 | |
| Tyrosine SCHEMBL9732471 | 0.81 | SLC7A5 (0.65) | GRM8GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 518 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340912-A1 | METHOD FOR PRODUCING 2,4-DIHYDROXY BUTYRATE OR L-THREONINE USING A MICROBIAL METABOLIC PATHWAY | Technische Universität Dresden (DE) | 2025-11-06 | — | — | US | claimed |
| US-20250236522-A1 | METHOD OF RECOVERING AND REUSING PHOSPHORIC ACID FROM FERMENTATION BROTH OR FERMENTATION WASTE LIQUID | CJ CHEILJEDANG CORPORATION (KR) | 2025-07-24 | — | — | US | claimed |
| EP-4474481-A1 | METHOD FOR RECOVERING PHOSPHORIC ACID FROM FERMENTATION BROTH OR FERMENTATION WASTE LIQUID AND REUSING SAME | CJ CheilJedang Corporation (KR) | 2024-12-11 | — | — | EP | claimed |
| CN-118922552-A | Method for recovering phosphoric acid from fermentation liquid or fermentation waste liquid and recycling phosphoric acid | CJ第一制糖株式会社 | 2024-11-08 | — | — | CN | claimed |
| EP-3562950-B1 | PROCESS FOR THE SYNTHESIS OF FUNCTIONALIZED CYCLIC DITHIOCARBAMATES | ARKEMA FRANCE (FR) | 2024-10-02 | — | — | EP | claimed |
| CN-110869503-B | Methionine producing yeast | 安迪苏法国联合股份有限公司 | 2024-09-27 | — | — | CN | claimed |
| US-20240254525-A1 | METHOD FOR THE INCORPORATION OF FORMALDEHYDE INTO BIOMASS | SCIENTIST OF FORTUNE S.A. (LU) | 2024-08-01 | — | — | US | claimed |
| EP-4376826-A1 | AMINO ACID COMPOSITIONS AND METHODS FOR USE IN THE TREATMENT OF POST-ACUTE SEQUELAE OF COVID-19 | Axcella (Assignment for the benefit of Creditors), LLC (US) | 2024-06-05 | — | — | EP | claimed |
| US-11976310-B2 | Method for the incorporation of formaldehyde into biomass | SCIENTIST OF FORTUNE S.A. (LU) | 2024-05-07 | — | — | US | claimed |
| US-20240002893-A1 | PROCESS FOR SYNTHESIZING FUNCTIONALIZED MERCAPTANS UNDER AN H2S PRESSURE | ARKEMA FRANCE (FR) | 2024-01-04 | — | — | US | claimed |
| WO-2008152444-A2 | FOAMABLE WATERLESS COMPOSITIONS WITH MODULATING AGENTS | FOAMIX LTD. (US) | 2008-12-18 | — | — | WO | claimed |
| US-20080206159-A1 | Drug mixture contains solvents, nonionic surfactants, gelling agent, therapeutic active agent, liquefied or compressed gas propellant; pressurized dispenser; treating skin diseases, dermal and mucosal delivery; stable and non-irritating emulsions | FOAMIX LTD. (IL) | 2008-08-28 | — | — | US | claimed |
| EP-1649857-A2 | New use of glutamate antagonists for the treatment of cancer | Ikonomidou, Hrissanthi (DE) | 2006-04-26 | — | — | EP | claimed |
| US-20050054650-A1 | Use of glutamate antagonists for the treatment of cancer | IKONOMIDOU HRISSANTHI (DE) | 2005-03-10 | — | — | US | claimed |
| WO-2004021981-A2 | METHODS FOR THE PREPARATION OF β-AMINO ACIDS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2004-03-18 | — | — | WO | claimed |
| US-20030113882-A1 | Methods for the preparation of beta-amino acids | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2003-06-19 | — | — | US | claimed |
| EP-0797442-B1 | TREATMENT OF OPTIC NEURITIS | MASSACHUSETTS EYE & EAR INFIRM (US) | 2003-05-21 | — | — | EP | claimed |
| EP-1002535-A1 | New use of glutamate antagonists for the treatment of cancer | Ikonomidou, Hrissanthi (DE) | 2000-05-24 | — | — | EP | claimed |
| WO-1997027851-A1 | L-HOMOSERINE AND L-HOMOSERINE LACTONE AS BACTERIOSTATIC AGENTS FOR M. TUBERCULOSIS AND M. BOVIS | THE JOHNS-HOPKINS UNIVERSITY (US) | 1997-08-07 | — | — | WO | claimed |
| EP-0338790-A2 | Production of homoserine and its derivatives such as threonine derivatives and methionine precursors | BIOTECHNICA INTERNATIONAL, INC. (US) | 1989-10-25 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080206159-A1 | Drug mixture contains solvents, nonionic surfactants, gelling agent, therapeutic active agent, liquefied or compressed gas propellant; pressurized dispenser; treating skin diseases, dermal and mucosal delivery; stable and non-irritating emulsions | CUTA, SLTM, SMO | GLUL 3852/4885GRM8 2310/4885GRM6 2292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.